BioCryst Pharmaceuticals (BCRX) Stock Forecast & Price Target

BioCryst Pharma is expected to have a positive outlook going forward, with a focus on three key updates: completion of Phase 3 enrollment and topline data on both 6- and 12-month efficacy endpoints for navenibart in Q3 2027, availability of ORLADEYO oral pellets for patients aged 2 to <12 years in early August 2026, and proof-of-concept data for BCX17725 expected by year-end 2026. These updates demonstrate a more disciplined allocation of resources and a sharpened focus on rare disease pipeline expansion beyond ORLADEYO, potentially leading to long-term profitability. Key financial highlights include a potential revenue of over $1 billion and a reduction in non-GAAP operating expenses to $420-440 million in 2026. With a positive phase 3 navenibart readout and the potential for BCX17725 to become commercially available, BioCryst Pharma remains an Outperform rated investment with a target of $21.

BioCryst Pharma is a biotechnology company with a negative outlook due to concerns about potential manufacturing issues and competition for their flagship product, Orladeyo, from PHVS. While the company has a promising pipeline in rare disorders, they face regulatory and commercial challenges that could limit their ability to gain traction in the market. Furthermore, the recent data on Orladeyo's efficacy in pediatric patients shows a decline in attack rate requiring treatment, but the shorter time frame of the data may not be indicative of long-term success. Considering this, the company's financial performance may also be impacted as they face potential hurdles in gaining regulatory approval and maintaining positive retention among existing HAE patients.